Respiratory Tract Infection Treatment Market Size Report | 2031

Respiratory Tract Infection Treatment Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug (Antibiotics, NSAIDs, Cough Suppressants, Nasal Decongestants, and Others), Disease Indication (Upper Respiratory Tract Infection and Lower Respiratory Tract Infection), Route of Administration (Oral and Parenteral), Age Group (Pediatric and Adult), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), and Geography

  • Report Code : TIPRE00003835
  • Category : Pharmaceuticals
  • No. of Pages : 150
Buy Now

Respiratory Tract Infection Treatment Market Size Report | 2031

Buy Now

The respiratory tract infection treatment market size is expected to reach US$ 69.13 billion by 2031 from US$ 43.6 billion in 2023; it is anticipated to register a CAGR of 5.93% during 2023–2031.

Respiratory tract infections, or RTIs, are infections of the sinuses, throat, airways, or lungs. The global respiratory tract infection treatment market report emphasizes the key factors driving the market and depicts the developments of prominent players. Key factors driving the market growth include the rising prevalence of respiratory infections globally, increasing awareness related to respiratory tract infections and various therapeutics related to respiratory tract infection, and increasing number of clinical trials related to respiratory tract infection treatment. However, the lack of research focused on respiratory therapeutics and adverse effects related to respiratory infection drugs hinders market growth. Further, the advent of antiviral treatment is expected to bring new global respiratory tract infection treatment market trends in the coming years.

Growth Drivers and Restraints:

Rising Demand for Respiratory Disease Diagnosis Among Elderly Population

As the elderly population has grown globally, the demand for the diagnosis of respiratory diseases is anticipated to increase in the coming years. For instance, according to an article published in the British Journal of Pharmacology in November 2021, ~1% of the UK population is diagnosed with community-acquired pneumonia (CAP) annually. Approximately 70% of cases occur in those aged over 65, and the 30-day mortality is approximately 20% in this age group. Thus, the rise in the aging population and increase in the incidence of diseases such as CAP is expected to propel the demand for respiratory disease treatments, boosting the overall market growth.

Continuous research and development in this field has resulted in various diagnostic tests and procedures that will positively affect the growth of the market in the coming years. Innovative diagnostic methods are expected to offer good opportunities for market development during the forecast period. However,  the scarcity of research studies and adverse reactions related to respiratory tract infection drugs is expected to limit the global respiratory tract infection treatment market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Respiratory Tract Infection Treatment Market: Strategic Insights

Respiratory Tract Infection Treatment Market

  • CAGR (2023 - 2031)
    5.93%
  • Market Size 2023
    US$ 43.6 Billion
  • Market Size 2031
    US$ 69.13 Billion

Market Dynamics

GROWTH DRIVERS
  • Rising prevalence of respiratory disorders
FUTURE TRENDS
  • Adoption of Combination Treatment for Respiratory Infection
OPPORTUNITIES
  • Advent of antiviral treatment for respiratory diseases

Key Players

  • Abbott,
  • AsteraZeneca,
  • Cipla,
  • Merck & Co. ,
  • GlaxoSmithkline plc
  • Novartis AG

Regional Overview

  • North America
  • Europe
  • Asia-Pacific
  • South and Central America
  • Middle East and Africa

Market Segmentation

Drug
  • Antibiotics
  • NSAIDs
  • Cough Suppressants
  • Nasal Decongestants
  • Others
Disease Indication
  • Upper Respiratory Tract Infection and Lower Respiratory Tract Infection
Age Group
  • Pediatric and Adult
Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Report Segmentation and Scope:

The global respiratory tract infection treatment market analysis has been carried out by considering the following segments: drug disease indication, route of administration, age group, and distribution channel. Based on drugs, the market is differentiated into antibiotics, NSAIDs, cough suppressants, nasal decongestants, and others. By disease indication, the global respiratory tract infection treatment market is segmented into upper respiratory tract infection and lower respiratory tract infection. In terms of route of administration, the market is differentiated into oral and parenteral. On the basis of age group, the market is classified into pediatric and adult. Based on distribution channel, the global respiratory tract infection treatment market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.

Segmental Analysis:

In terms of drug, the antibiotics segment held the largest global respiratory tract infection treatment market share in 2023. The segment is anticipated to register the highest CAGR during 2023–2031. Respiratory tract infections encompass a range of ailments, including bronchitis, pneumonia, and sinusitis, often caused by bacterial pathogens. Antibiotics target and eliminate these harmful bacteria, reducing inflammation and promoting faster recovery. Commonly prescribed antibiotics for respiratory tract infections include penicillins, cephalosporins, macrolides, fluoroquinolones, and tetracyclines, and each of these has unique action mechanisms and bacterial targets.

Based on disease indication, the lower respiratory tract infection segment held a larger market share in 2023. It is further anticipated to register a higher CAGR from 2023 to 2031. Lower respiratory tract infections (LRTIs) are infections that affect the lungs and bronchial tubes, typically caused by bacterial, viral, or fungal pathogens, among others. Conditions such as pneumonia, bronchitis, and bronchiolitis, which typically exhibit symptoms such as productive cough, chest discomfort, shortness of breath, and fever, are categorized under the spectrum of LRTIs. Pneumonia, a severe LRTI, involves inflammation and infection of the lung tissue, leading to pulmonary consolidation (some areas of the lung or the complete organ) and impaired gas exchange.

By route of administration, the oral segment held a larger share of the global respiratory tract infection treatment market; the segment is anticipated to register a higher CAGR during 2023–2031. Oral antibiotics such as amoxicillin, azithromycin, or doxycycline are frequently prescribed to combat bacterial pathogens causing respiratory tract infections. In addition to antibiotics, oral corticosteroids may reduce inflammation in severe asthma or chronic obstructive pulmonary disorder (COPD) exacerbations. Oral antiviral medications such as oseltamivir are utilized for treating viral respiratory infections such as influenza. The common advantages of the oral route include easy administration, patient compliance, and systemic drug distribution.

In terms of age group, the adult segment held a larger share of the global respiratory tract infection treatment market in 2023. The pediatrics segment is anticipated to register a higher CAGR during 2023–2031. Factors such as the awareness related to the importance of early diagnosis and treatment of respiratory infections in children and advancements in respiratory devices used for treatment are leading to the development of new and more effective treatment options. Moreover, the growing focus on preventive healthcare is contributing to the growth of the market for the pediatric segment.

In terms of distribution channel, the hospital pharmacies segment is anticipated to account for a significant market share during 2023–2031. Hospital pharmacies serve as key components of a healthcare system; they particularly play a vital role in the management of acute and severe respiratory tract infections, which require intravenous or intramuscular administration of medications. These pharmacies are responsible for sourcing, storing, and dispensing antibiotics, antivirals, corticosteroids, and other respiratory infection treatments, as well as ensuring their safe and timely delivery to inpatient and outpatient settings in hospitals.

Respiratory Tract Infection Treatment Market Report Scope

Report Attribute Details
Market size in 2023 US$ 43.6 Billion
Market Size by 2031 US$ 69.13 Billion
Global CAGR (2023 - 2031) 5.93%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Drug
  • Antibiotics
  • NSAIDs
  • Cough Suppressants
  • Nasal Decongestants
  • Others
By Disease Indication
  • Upper Respiratory Tract Infection and Lower Respiratory Tract Infection
By Age Group
  • Pediatric and Adult
By Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Abbott,
  • AsteraZeneca,
  • Cipla,
  • Merck & Co. ,
  • GlaxoSmithkline plc
  • Novartis AG
    • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

    Regional Analysis:

    The growing awareness among the population about the importance of early diagnosis and treatment of respiratory infections is likely to contribute to the global respiratory tract infection treatment market growth in the coming years. The market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South and Central America. North America held the largest global respiratory tract infection treatment market share in 2023. The market in North America is experiencing significant growth owing to the elevated prevalence of respiratory tract infections in the country. Factors such as air pollution, smoking, and crowded living conditions contribute to the high incidence of respiratory infections in the country. Increase in the prevalence of respiratory infections, a rise in awareness about healthcare, and favorable initiatives by the government are driving the global respiratory tract infection treatment market growth.

    Competitive Landscape and Key Companies:

    The global respiratory tract infection treatment market forecast can help stakeholders plan their growth strategies. Abbott Laboratories, AstraZeneca plc, Alembic Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Novartis AG, F. Hoffmann-La Roche AG, Sanofi S.A., Merck & Co., Cipla are among the prominent players profiled in the global respiratory tract infection treatment market report. These companies focus on various strategies (including both organic and inorganic) to meet the burgeoning consumer demand and expand their product range in specialty portfolios. The major strategies adopted by the companies in the market include new technology launches, existing product developments, and geographic expansions.

    Report Coverage
    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered
    Segment Covered

    This text is related
    to segments covered.

    Regional Scope
    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope
    Country Scope

    This text is related
    to country scope.

    Frequently Asked Questions


    What is respiratory tract infection treatment?

    Respiratory diseases such as asthma, bronchitis, allergic rhinitis, pneumonia and sinusitis can seriously impair a person's physical functioning. Symptoms associated with both mild and severe diseases of these respiratory tracts include cough, wheezing, chest pain, difficulty breathing, and shortness of breath, congestion and, in severe cases, even death. These conditions cause significant morbidity and high costs to society. Treatment of the above respiratory disease is known as respiratory tract infection treatment.

    What factors drive the respiratory tract infection treatment market?

    The key factors driving the respiratory tract infection treatment market growth are the demand for the diagnosis of respiratory diseases owing to the rising prevalence of these diseases coupled with rising demand for OTC products. In addition, continuous research and development in this field has resulted in various diagnostic tests and procedures that will positively affect the growth of the market in the coming years.

    What was the estimated respiratory tract infection treatment market size in 2023?

    The respiratory tract infection treatment market was valued at US$ 43.60 billion in 2023.

    What are the growth estimates for the respiratory tract infection treatment market till 2031?

    The respiratory tract infection treatment market is expected to be valued at US$ 69.13 billion in 2031.

    Who are the major players in the respiratory tract infection treatment market?

    The respiratory tract infection treatment market has major market players, including Abbott Laboratories, AstraZeneca plc, Alembic Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Novartis AG, F. Hoffmann-La Roche AG, Sanofi S.A., Merck & Co and Cipla.

    Which drug segment dominates the respiratory tract infection treatment market?

    Based on drug, the market is segmented into Antibiotics, NSAIDs, Cough Suppressants, Nasal Decongestants, and Others. The antibiotics segment held the largest respiratory tract infection treatment market share in 2023 and is anticipated to register the highest CAGR during 2023–2031.

    Which disease indication segment dominates the respiratory tract infection treatment market?

    Based on disease indication, the respiratory tract infection treatment market is segmented into LRTI and URTI. The LRTI is anticipated to hold a significant share by 2031.

    The List of Companies - Respiratory Tract Infection Market

    1. Merck & Co
    2. Abbott
    3. AbbVie
    4. Sanofi
    5. GlaxoSmithKline plc
    6. F. Hoffmann La Roche Ltd.
    7. Pfizer, Inc.
    8. Novartis AG
    9. Teva Pharmaceuticals
    10. Boehringer Ingelheim GmbH

    Trends and growth analysis reports related to Pharmaceuticals : READ MORE..